Skip to content

Released May 3, 2023, after the close

10-Q filed May 3, 2023, 33 days after period end · 0000950170-23-017175

Q1 2023 · 10-Q
Revenue$58.98M+220.3% vs Q1 2022+33.0% vs Q4 2022
Net Income-$18.88MN/M vs Q1 2022N/M vs Q4 2022
EPS Diluted-$0.19N/M vs Q1 2022no prior Q4 2022 on file
Operating Income-$28,592,000N/M
Operating Cash Flow-$28,860,000N/M
Free Cash Flowderived-$32,068,000N/M
Margins · derived
Operating margin-48.5%+355.9 pt vs Q1 2022
Net margin-32.0%+324.7 pt vs Q1 2022

What the release said

The release

Same quarter

MetricQ1 2023Q1 2022Q1 2021Q1 2020
Revenue$58.98M$18.41M$11.14M$2.52M
Net Income-$18.88M-$65.69M-$45.09M-$33.52M
EPS Diluted-$0.19-$0.68-$0.48-$0.44

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR